ArticleSurgical endoscopy2022
Oncological outcomes according to the treatment modality based on the size of rectal neuroendocrine tumors: a single-center retrospective study.
Article in Surgical endoscopy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- NANETS Guidelines for the diagnosis and management of stage I-III rectal neuroendocrine tumors.Endocrine-related cancer · 2026Guideline
- Endoscopic mucosal resection using anchored snare Tip-in versus precut technique for small rectal neuroendocrine tumors.The Korean journal of internal medicine · 2024Trial
- Factors Influencing Resection Time in Endoscopic Submucosal Dissection for Rectal Neuroendocrine Tumors.DEN open · 2026Article
- Analysis of the efficacy and safety of endoscopic full-thickness resection in the treatment of rectal neuroendocrine tumors.Frontiers in medicine · 2026Article
- The efficacy of endoscopic submucosal dissection for 10-20 mm rectal neuroendocrine tumors based on resection margin status.Surgical endoscopy · 2025Article
- Rectal Neuroendocrine Tumor With Non-Atypical Mucous Cell Glands: A Case Report.JGH open : an open access journal of gastroenterology and hepatology · 2025Article
- Submucosal saline injection and mini-probe endoscopic ultrasound to assess endoscopic resectability of colorectal subepithelial tumors.The Korean journal of internal medicine · 2025Article
- Impact of grade on workup of rectal neuroendocrine tumors: a retrospective cohort study : Grade impact on workup of rectal NETs.World journal of surgical oncology · 2024Article
- Risk Factor Analysis of Lymph Node Metastasis for Rectal Neuroendocrine Tumors: Who Needs a Radical Resection in Rectal Neuroendocrine Tumors Sized 1-2 cm?Annals of surgical oncology · 2024Article
- Clinical outcomes and risk factors associated with poor prognosis after endoscopic resection of 10-20 mm rectal neuroendocrine tumors: a multicenter, retrospective study of 10-year experience.Surgical endoscopy · 2023Article
- Current status of the role of endoscopy in evaluation and management of gastrointestinal and pancreatic neuroendocrine tumors.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Review
- Rectal Neuroendocrine Neoplasms: Why Is There a Global Variation?Current oncology reports · 2022Review
- Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOwing to an increased number of colonoscopy screenings, the incidence of diagnosed rectal neuroendocrine tumors (NETs) has also increased. Tumor size is one of the most frequently regarded factors when selecting treatment; however, it may not be the determinant prognostic variable. We aimed to evaluate oncological outcomes according to the treatment modality based on the size of rectal NETs.
methodsA retrospective analysis was performed on patients who were treated for rectal NETs between March 2000 and January 2016 at the Asan Medical Center, Seoul, Korea. Patients who underwent endoscopic removal, local surgical excision, and radical resection were included. The primary outcome was recurrence-free survival (RFS). Data were specified and analyzed following the 2019 World Health Organization classification (WHO).
resultsA total of 644 patients were categorized under three groups according to the treatment modality used: endoscopic removal (n = 567), surgical local excision (n = 56), and radical resection (n = 21). Of a total of 35 recurrences, 27 were local, whereas eight were distant. The RFS rate did not differ significantly between the treatment groups in the same tumor-size group ([Formula: see text]1 cm group: P = .636, 1-2 cm group: P = .160). For T1 tumors, RFS rate was not different between local excision and radical resection ([Formula: see text]1 cm group: P = .452, 1-2 cm group: P = .700). Depth of invasion, a high Ki-67 index, and margin involvement were confirmed as independent risk factors for recurrence. Among patients treated with endoscopic removal, endoscopic biopsy was a significant factor for worse RFS (P < .001), while tumor size did not affect the RFS.
conclusionThe current guideline recommends treatment options according to tumor size. However, more oncologically important prognostic factors include muscularis propria invasion and a higher Ki-67 index.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.